Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use disorder (OUD) on patients treated for 24 weeks, with real-world evidence demonstrating that the treatment is associated with improved outcomes, high levels of […]
Clinical Trials
Oramed hits 50% enrollment in Phase 2 trial for oral insulin capsule
Oramed Pharmaceuticals (NSDQ:ORMP) announced today that it reached over 50% enrollment in a trial for its oral insulin treatment. New York-based Oramed’s Phase 2 trial evaluates its oral insulin capsule ORMD-0801 for the treatment of non-alcoholic steatohepatitis (NASH), with patients continuing to be screened at sites in the U.S. and Israel, according to a news […]
Lyra touts non-human trial of XTreo drug-eluting implant
Lyra Therapeutics (NSDQ:LYRA) is touting preclinical data for its XTreo drug-eluting implant for dosing in local sinus tissues. Watertown, Massachusetts-based Lyra’s preclinical results were published — “Drug Release and Pharmacokinetic Evaluation of Novel Implantable Mometasone Furoate Matrices in Rabbit Maxillary Sinuses” — were published online in the peer-review journal, American Journal of Rhinology & Allergy. The […]
Dermavant doses first patient in trial of topical cream for atopic dermatitis
Dermavant Sciences announced today that it dosed the first patient in a Phase 3 pivotal study of its atopic dermatitis (AD) treatment. Long Beach, California-based Dermavant’s double-blind, vehicle-controlled pivotal study evaluates tapinarof for the treatment of AD, according to a news release. The company developed tapinarof as an investigational novel, therapeutic aryl hydrocarbon receptor modulating […]
AFYX touts trial of biodegradable drug delivery patch
AFYX Therapeutics today touted results from a study exploring the delivery of antibody fragments using the company’s Rivelin technology. The preclinical study, conducted in collaboration with the University of Sheffield in the United Kingdom, evaluated Rivelin for delivering the antibody fragments directly to inflamed tissue in mucosal diseases. According to a news release, results demonstrated […]
TriSalus enrolls first patient in pressure-enabled drug delivery trial for treating melanoma
TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma. The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors […]
Fractyl activates 10th clinical site in diabetes reversal tech trial
Fractyl Health announced today that it activated the 10th clinical site in its pivotal REVITA-T2Di trial in the U.S. and Europe. Lexington, Mass.-based Fractyl’s trial is enrolling patients with type 2 diabetes who are currently on insulin therapy at sites in New Jersey, Louisiana, Texas, Massachusetts and New York to add to the initial U.S. […]
MedAlliance enrolls first patient in drug-eluting balloon trial for erectile dysfunction
MedAlliance announced today that it enrolled the first patient in an erectile dysfunction (ED) feasibility study with its drug-eluting balloon (DEB). Nyon, Switzerland-based MedAlliance’s first patient was enrolled in the trial at the University of Rome Tor Vergata, Italy, under principal investigator Giuseppe Sangiorgi, a professor of cardiovascular interventional pathology. According to a news release, […]
Sinomed launches HT Supreme drug-eluting stent in Europe
Sinomed has completed the first commercial implantation of its HT Supreme drug-eluting stent in Ireland. Faisal Sharif, professor of translational cardiovascular medicine and innovation at the National University of Ireland Galway, successfully performed the first procedure with HT Supreme, a healing-targeted drug-eluting stent designed to treat patients with narrowing or blockages to their coronary arteries. […]
MedAlliance closes enrollment for sirolimus-coated balloon trial
MedAlliance announced today that it closed patient enrollment for its clinical trial of the Selution SLR 018 BLF drug-eluting balloon. Nyon, Switzerland–based MedAlliance designed its Selution SLR 018 BLF for the treatment of patients with disease below the knee. The company touts Selution SLR as the first device of its kind to receive an “innovative […]